Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06848101

Eye and Carotenoid Augmentation Research and Evaluation (EyeCARE)

The primary study outcomes are to investigate the effects of 4-month daily carotenoid complex supplementation on carotenoid status in the macula and skin and visual fatigue among adults 20-45 years of age. Secondary outcomes will examine the supplementation effects on cognitive function.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Age range

20 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of illinois

Urbana, Illinois, 61801, United States

About this study

Lutein and zeaxanthin are carotenoids or plant-based pigments that accumulate in various human tissues including the eye, skin, adipose/fat, and the brain where they play important roles as antioxidants and light filters. Previous correlational work has shown that lutein and zeaxanthin intake is associated with multiple markers of health including visual and cognitive outcomes. However, experimental or intervention research examining the effects of lutein and zeaxanthin supplementation on the accumulation of these carotenoids in the eye and skin and implications for visual and cognitive function is still emerging. Additionally, virtually all the previous research has relied on single nutrient supplementation (e.g., only lutein or zeaxanthin) resulting in limited knowledge of the benefits of providing these carotenoids with other possibly healthful nutrients (e.g., astaxanthin, vitamin E). Accordingly, this project will test the effects of lutein and zeaxanthin supplementation provided in a complex with other antioxidants and nutrients on outcomes of nutritional status in the eye and skin as well as visual and cognitive health. The study aims will be addressed using a double-blind randomized controlled trial design. Adults 20-45 years of age will be asked to participate in a daily 4-month double-blind randomized controlled clinical trial. Treatment group (N=20) participants will be asked to consume 2 daily softgels with a daily total containing 20mg free lutein (10mg/softgel), 4 mg free zeaxanthin (2mg/softgel), 40mg maqui berry extract (20mg/softgel), 6 mg astaxanthin (3 mg/softgel), 80mg bilberry extract (40mg/softgel), flaxseed oil (150mg/softgel), and vitamin E (5IU/softgel). Participants will be asked to consume the supplements with a meal of their choosing. Control group participants will be asked to consume similar-looking placebo softgels over the same period.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • not pregnant
  • not breastfeeding
  • absence of hypertension
  • absence of diabetes
  • absence of cerebrovascular disease
  • absence of cardiovascular disease
  • absence of liver disease
  • absence of kidney disease
  • absence of gastrointestinal disease
  • absence of age-related macular degeneration
  • no allergy to carotenoids
  • 20/20 or corrected vision
  • MPOD less than or equal to 0.60
  • Age between 20-45 years

Exclusion criteria

  • pregnant
  • breastfeeding
  • presence of hypertension
  • presence of diabetes
  • presence of cerebrovascular disease
  • presence of cardiovascular disease
  • presence of liver disease
  • presence of kidney disease
  • presence of gastrointestinal disease
  • presence of age-related macular degeneration
  • allergy to carotenoids
  • not 20/20 or uncorrected vision
  • MPOD greater than 0.60
  • Younger than 20 years or older than 45 years

Treatment and study plan

Carotenoid Group

Dietary Supplement

Treatment will contain 20mg free lutein (10mg/softgel), 4 mg free zeaxanthin (2mg/softgel), 40mg maqui berry extract (20mg/softgel), 6 mg astaxanthin (3 mg/softgel), 80mg bilberry extract (40mg/softgel), flaxseed oil (150mg/softgel), and vitamin E (5IU/softgel)

Control (placebo) group

Dietary Supplement

Flaxseed Oil (330mg)

Primary outcomes

  1. Macular Pigment Optical Density

    Time frame: From enrollment to end of treatment at 4 months

    Macular carotenoids assessed using heterochromatic flicker photometry

Secondary outcomes

  1. Skin carotenoids

    Time frame: From enrollment to end of treatment at 4 months

    Carotenoids in skin assessed using skin reflection spectroscopy

  2. Visual Fatigue

    Time frame: From enrollment to end of treatment at 4 months

    Visual fatigue as assessed by the Computer Vision Syndrome Questionnaire

Sponsors and collaborators

Lead sponsor

University of Illinois at Urbana-Champaign

Other

Collaborators

  • Daiken Biomedical Co., Ltd.

Registry information

Acronym: EyeCARE

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Feb 26, 2025
Registry last updated
Feb 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.